TACR1
Substance-P receptor
As of the edition of 20 October 2026, TACR1 (substance-P receptor, UniProt P25103) has 16 drugs tested at it and 20 companies on the list, 7 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25103
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 15
- Disease areas
- Cancer; Mental health; Skin and connective tissue; Hormones; Immune system; Inherited and neonatal; Blood and lymph; Digestive system
- Registered trials of its drugs
- 313
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 5 |
| Stopped | 4 |
| Total | 16 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aprepitant | Marketed | Phase 4 | none listed |
| Fosaprepitant | Marketed | Phase 4 | none listed |
| Casopitant | Went quiet | Phase 3 | none listed |
| Tradipitant | Marketed | Phase 3 | Ends 2030 |
| Elinzanetant | Marketed | Phase 3 | Ends 2030 |
| Netupitant | Marketed | Phase 4 | Ends 2035 |
| Rolapitant | Marketed | Phase 3 | Ends 2028 |
| Serlopitant | Stopped | Phase 3 | none listed |
| Orvepitant | Stopped | Phase 2 | none listed |
| Vestipitant | Went quiet | Phase 2 | none listed |
| DNK333 | Went quiet | Phase 2 | none listed |
| AV608 | Stopped | Phase 2 | none listed |
12 of 16 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 20 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| GSK | Route A |
| Vanda Pharmaceuticals | Route B |
The other 17 companies at TACR1
In the product20 companies in all; 17 are not named here, and no score is.
See the 20 companies at TACR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.